Cargando…

Role of Paricalcitol in Modulating the Immune Response in Patients with Renal Disease

Introduction. The aim was to highlight the existence of a relationship between vitamin D deficiency, chronic inflammation, and proteinuria, by measuring neutrophil gelatinase associated lipocalin (NGAL) and common inflammatory markers after administration of paricalcitol, a vitamin D analog, in vivo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lucisano, Silvia, Arena, Adriana, Stassi, Giovanna, Iannello, Daniela, Montalto, Gaetano, Romeo, Adolfo, Costantino, Giuseppe, Lupica, Rosaria, Cernaro, Valeria, Santoro, Domenico, Buemi, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586963/ https://www.ncbi.nlm.nih.gov/pubmed/26451144 http://dx.doi.org/10.1155/2015/765364

Ejemplares similares

Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide
por: Cernaro, Valeria, et al.
Publicado: (2016)

Both IL-1β and TNF-α Regulate NGAL Expression in Polymorphonuclear Granulocytes of Chronic Hemodialysis Patients
por: Arena, Adriana, et al.
Publicado: (2010)

Role of Vitamin D Status in Diabetic Patients with Renal Disease
por: Gembillo, Guido, et al.
Publicado: (2019)

Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease
por: Visconti, Luca, et al.
Publicado: (2016)

Beneficial effects of oral pure caffeine on oxidative stress
por: Metro, Daniela, et al.
Publicado: (2017)

Xanthine Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis
por: Pisano, Anna, et al.
Publicado: (2017)

Socio-Economic Factors, Food Habits and Phosphorus Levels in Patients on Hemodialysis
por: Santoro, Domenico, et al.
Publicado: (2015)

Vascular access for hemodialysis: current perspectives
por: Santoro, Domenico, et al.
Publicado: (2014)

Interplay of Vitamin D, Erythropoiesis, and the Renin-Angiotensin System
por: Santoro, Domenico, et al.
Publicado: (2015)

Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease
por: Cernaro, Valeria, et al.
Publicado: (2020)

Protective Role of Vitamin D in Renal Tubulopathies
por: Gembillo, Guido, et al.
Publicado: (2020)

Renal amyloidosis in cystic fibrosis: role of colchicine therapy
por: Santoro, Domenico, et al.
Publicado: (2014)

Antioxidant agents for delaying diabetic kidney disease progression: A systematic review and meta-analysis
por: Bolignano, Davide, et al.
Publicado: (2017)

Cardiac and Renal Effects of Atrasentan in Combination with Enalapril and Paricalcitol in Uremic Rats
por: Ritter, Cynthia, et al.
Publicado: (2014)

Complement Inhibition Therapy and Dialytic Strategies in Paroxysmal Nocturnal Hemoglobinuria: The Nephrologist’s Opinion
por: Gembillo, Guido, et al.
Publicado: (2020)

Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients
por: Pihlstrøm, Hege Kampen, et al.
Publicado: (2020)

Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics
por: Arenas Jimenez, María Dolores, et al.
Publicado: (2021)

Antiapoptotic Effect of Paricalcitol in Gentamicin-induced Kidney Injury
por: Suh, Sang Heon, et al.
Publicado: (2013)

Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients
por: Izquierdo, María Jesús, et al.
Publicado: (2012)

Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology
por: Pontremoli, Roberto, et al.
Publicado: (2020)

Correlation between Hyperkalemia and the Duration of Several Hospitalizations in Patients with Chronic Kidney Disease
por: Calabrese, Vincenzo, et al.
Publicado: (2022)

Paricalcitol as an Antiproteinuric Agent Can Result in the Deterioration of Renal and Heart Function in a Patient with Fabry Disease
por: Keber, Tajda, et al.
Publicado: (2017)

Anti-inflammatory and anti-apoptotic effects of paricalcitol in lipopolysaccharide-induced renal proximal tubular cell injury
por: Kim, Soo Wan
Publicado: (2017)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Protective Effects of Paricalcitol on Peritoneal Remodeling during Peritoneal Dialysis
por: Stavenuiter, Andrea W. D., et al.
Publicado: (2015)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
por: Cruzado, Josep M., et al.
Publicado: (2017)

Effects of Paricalcitol on Body Composition in Vitamin D-Deficient Rats
por: Koohpeyma, Farhad, et al.
Publicado: (2021)

Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
por: Chen, Xiu, et al.
Publicado: (2021)

Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation
por: D’Marco, Luis, et al.
Publicado: (2022)

Chronic Kidney Disease Requiring Healthcare Services: A New Approach to Evaluate Epidemiology of Renal Disease
por: Trifirò, Gianluca, et al.
Publicado: (2014)

Effects of paricalcitol combined with hemodiafiltration on bone-metabolism-related indexes in patients with diabetic nephropathy and chronic renal failure
por: Ma, Xiao-Ying, et al.
Publicado: (2023)

Almond Skin Inhibits HSV-2 Replication in Peripheral Blood Mononuclear Cells by Modulating the Cytokine Network
por: Arena, Adriana, et al.
Publicado: (2015)

Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study
por: De Nicola, Luca, et al.
Publicado: (2012)

Comparison of the Pharmacological Effects of Paricalcitol and Doxercalciferol on the Factors Involved in Mineral Homeostasis
por: Wu-Wong, J. Ruth, et al.
Publicado: (2010)

Asymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol
por: Oliva-Damaso, Elena, et al.
Publicado: (2016)

Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis
por: Liu, Yang, et al.
Publicado: (2019)

Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin
por: Chung, Sungjin, et al.
Publicado: (2017)

Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E(2) Receptor EP4 Pathway
por: Hong, Yu Ah, et al.
Publicado: (2017)

Autoimmune Thyroiditis and Glomerulopathies
por: Santoro, Domenico, et al.
Publicado: (2017)

Maternal and Fetal Outcomes of Pregnancy in Nephrotic Syndrome Due to Primary Glomerulonephritis
por: Siligato, Rossella, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tbirfhiud9g1iofv07jrvnejce